- Home
- HIO vs ZBIO Comparison
HIO vs ZBIO Comparison
Compare HIO & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIO
- ZBIO
- Stock Information
- Founded
- HIO 1993
- ZBIO 2019
- Country
- HIO United States
- ZBIO United States
- Employees
- HIO N/A
- ZBIO N/A
- Industry
- HIO Finance/Investors Services
- ZBIO
- Sector
- HIO Finance
- ZBIO
- Exchange
- HIO Nasdaq
- ZBIO NYSE
- Market Cap
- HIO 371.4M
- ZBIO 389.2M
- IPO Year
- HIO N/A
- ZBIO 2024
- Fundamental
- Price
- HIO $3.85
- ZBIO $7.77
- Analyst Decision
- HIO
- ZBIO Strong Buy
- Analyst Count
- HIO 0
- ZBIO 7
- Target Price
- HIO N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- HIO 305.3K
- ZBIO 198.9K
- Earning Date
- HIO 01-01-0001
- ZBIO 05-16-2025
- Dividend Yield
- HIO 10.33%
- ZBIO N/A
- EPS Growth
- HIO N/A
- ZBIO N/A
- EPS
- HIO N/A
- ZBIO N/A
- Revenue
- HIO N/A
- ZBIO $5,000,000.00
- Revenue This Year
- HIO N/A
- ZBIO N/A
- Revenue Next Year
- HIO N/A
- ZBIO N/A
- P/E Ratio
- HIO N/A
- ZBIO N/A
- Revenue Growth
- HIO N/A
- ZBIO N/A
- 52 Week Low
- HIO $3.52
- ZBIO $5.83
- 52 Week High
- HIO $4.03
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- HIO 25.17
- ZBIO N/A
- Support Level
- HIO $4.03
- ZBIO N/A
- Resistance Level
- HIO $4.04
- ZBIO N/A
- Average True Range (ATR)
- HIO 0.04
- ZBIO 0.00
- MACD
- HIO -0.02
- ZBIO 0.00
- Stochastic Oscillator
- HIO 1.85
- ZBIO 0.00
About HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.